In this respect, it could be interesting to exploit the effect of specific inhibitors of the DDR kinases as novel drugs to be administered either alone/in combination with classic ET drugs (e.g., 4OH-Tam) or with novel compounds (e.g., CDK4/CDK6 inhibitors) used for the management of metastatic BC. This evidence concerns the gene CDK6 and breast cancer.